The greatest hazard of mortality was observed within the first year after measurement.
The hazard of mortality increased progressively with non-CABG BARC grades.
There were no significant differences in the hazard of mortality or myocardial infarction between bevacizumab use and the other therapies.
Controlling for other variables, OPTIMIZE-HF patients were similar to non-OPTIMIZE-HF patients for the hazard of mortality (hazard ratio, 1.02; 95% confidence interval, 0.98 to 1.06).
The inverse probability-weighted adjusted hazard of mortality at 3 years for patients receiving an ICD was 0.71 (95% CI, 0.56 to 0.91).
The differences persisted after adjustment for baseline patient and hospital characteristics (hazard of readmission 1.10 [95% CI 1.02-1.18], hazard of mortality 1.53 [95% CI 1.34-1.75]).
Specifically, the hazard of mortality was significantly lower with ranibizumab therapy than with photodynamic therapy (hazard ratio, 0.85; 99% confidence interval, 0.75-0.95) or pegaptanib use (0.84; 0.74-0.95), and the hazard of myocardial infarction was significantly lower with ranibizumab use than with photodynamic therapy (0.73; 0.73-0.73).
For patients with EF ≤ 40%, the hazard of mortality increased by 26% for every 5% decrease in EF, a finding that remained after risk adjustment (adjusted HR 1.11, 95% CI 1.09-1.12).Low EF after MI remains an important risk factor for postdischarge mortality and hospital readmission, even after adjustment for patient and hospital characteristics.
The increased hazard of mortality implies that PLWH with TB die earlier compared to PLWH without TB.
The del/del genotype was associated with increased hazard of mortality at 60 days among patients with ARDS when compared to other genotypes (P = .04).04
Stratifying the studies per region showed that TB was significantly associated with an increased hazard of mortality in PLWH in the USA and Africa and reaching statistically significance in Europe (Table 1, Analyses 6.1 6.4).
